logologo
Search or Ask Iris
Ctrl+K
arrow
ToolBar Logo
Fabtech Technologies Ltd

Fabtech Technologies Ltd

FABTECHMainboard

AI Mode

Ask IPO

Overview

Fabtech Technologies Limited is a global company specializing in comprehensive turnkey engineering solutions for the pharmaceutical, biotechnology, and healthcare industries. With a footprint in over 62 countries, particularly in emerging economies, the company provides end-to-end services from design to certification for aseptic manufacturing facilities. Fabtech operates as part of the Fabtech Group and utilizes an asset-light, integrated business model, procuring key equipment from related group entities. It leverages its proprietary in-house software, 'FabAssure', for efficient project management, planning, and execution, enhancing transparency and operational control.

Opening Date

Sep 29, 2025

Closing Date

Oct 01, 2025

Listing Date

Oct 07, 2025

IPO Type

Mainboard

IPO Status

Closed

Issue Size

230.35 Cr

Fresh Issue

230.35 Cr

Offer for Sale

Price Band

₹181 - ₹191

Lot Size

75

IPO Timeline

Sep 29, 2025
Open Date
Oct 01, 2025
Close Date
Oct 03, 2025
Allotment Date
Oct 06, 2025
Initiation of Refunds
Oct 07, 2025
Listing Date

Financials

Revenue

Profit After Tax (PAT)

IPO Objective

Our Company proposes to utilize the Net Proceeds from the Issue towards funding the following objects:

  • Funding the working capital requirements of our Company to support business operations and the execution of future projects in Fiscals 2026 and 2027.

  • Pursuing inorganic growth initiatives through strategic acquisitions of companies engaged in manufacturing process equipment and other critical components in India, the United Arab Emirates, Saudi Arabia, and Egypt.

  • Funding general corporate purposes, which may include meeting operational expenses, strengthening marketing capabilities, and other strategic initiatives as approved by the Board.

Key Performance Indicator

P/E Ratio

EPS

ROE

30.46%

ROCE

24.46%

RONW

26.83%

Debt to Equity Ratio

0.32

PAT Margin

13.83%

EBITDA Margin

14.07%

P/B

3.57

SWOT Analysis

Strengths

  • Acts as a key turnkey engineering solution provider with comprehensive, integrated start-to-finish service offerings for the pharma and biotech sectors.

  • Operates on an asset-light and integrated business model, leveraging related group entities for equipment procurement, which allows for scalability and cost-efficiency.

  • Utilizes proprietary in-house software, 'FabAssure', for advanced project management, enabling real-time monitoring, efficient execution, and enhanced transparency.

  • Possesses a diversified order book across various geographies and has a proven track record of executing complex projects in challenging environments.

Weaknesses

  • Significant revenue concentration from a limited number of large projects, making financial performance vulnerable to delays or cancellations of key contracts.

  • Heavy reliance on related group entities for procuring a significant portion of equipment, which can lead to potential conflicts of interest and supply chain dependencies.

  • Geographical concentration of projects in the GCC and MENA regions, exposing the business to geopolitical instability and economic fluctuations in these areas.

  • Predominantly operates on fixed-price contracts, which exposes the company to risks of cost overruns and potential reduction in profit margins.

Opportunities

  • Expansion in existing core regions like GCC, MENA, and ECO by establishing a stronger local presence through overseas subsidiaries or joint ventures.

  • Increasing government clientele in the African region by bidding for public healthcare infrastructure projects, capitalizing on the growing need for pharmaceutical facilities.

  • Pursuing inorganic growth through strategic acquisitions in key markets such as India, UAE, Saudi Arabia, and Egypt to enhance manufacturing capabilities and market penetration.

  • Diversifying the customer base by targeting non-pharmaceutical sectors like nutraceuticals and GMP-certified fast-moving consumer goods (FMCG).

Threats

  • Exposure to political, economic, and regulatory changes in multiple international jurisdictions, which can adversely affect project execution and financial stability.

  • Increasing competition from other domestic and international turnkey engineering solution providers in the pharmaceutical capex space.

  • Potential disruptions from geopolitical tensions, regional conflicts, and supply chain issues in key operating regions like the Middle East and Africa.

  • Changes in global economic conditions, such as inflation or interest rate hikes, which can impact clients' capital expenditure plans and demand for new projects.

Subscription Rate

CategoryShares Bid ForShares OfferedTimes Subscribed
Qualified Institutional Buyers46.08 L60.03 L0.77x
Non-Institutional Investors8.27 L18.01 L0.46x
Retail Individual Investors29.75 L42.02 L0.71x
Employee29.70 K54.95 K0.54x
Total84.39 L1.21 Cr0.70x